```html

Zollinger‑Ellison Syndrome (MEN1 Variant)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition characterized by one or more gastrin‑secreting tumors (gastrinomas) that cause excessive gastric acid production. When ZES occurs in the setting of multiple endocrine neoplasia type 1 (MEN 1), the gastrinomas are typically part of a broader genetic syndrome that also predisposes patients to tumors of the parathyroid glands, pituitary gland, and other pancreatic neuro‑endocrine tumors (PNETs).

• Prevalence: Isolated ZES affects ≈1–3 per million people. MEN 1 occurs in about 1 in 30,000 – 1 in 50,000 individuals, and roughly 20–30 % of MEN 1 patients develop ZES.
• Typical age of onset: Gastrinomas usually appear in the 3rd–4th decade of life; in MEN 1 the diagnosis may be made earlier because of routine screening of family members.
• Gender: Both sexes are equally affected.

Because ZES is driven by a genetic mutation (most often in the MEN1 tumor‑suppressor gene), it is considered hereditary. Understanding the link between ZES and MEN 1 is essential for patients, families, and clinicians.

Symptoms

Excess gastric acid leads to a spectrum of gastrointestinal and systemic complaints. Symptoms may be intermittent early on and become more constant as the tumor grows.

Gastro‑intestinal (GI) symptoms

• Recurrent peptic ulcer disease: Ulcers often occur beyond the duodenum (e.g., jejunum, stomach) and may be multiple or refractory to standard therapy.
• Abdominal pain: Cramping or burning pain related to ulceration or acid irritation.
• Diarrhea: Occurs in 30–50 % of patients; may be watery and persistent due to acid inactivation of pancreatic enzymes.
• Steatorrhea (fatty stools): Resulting from malabsorption caused by acid‑induced pancreatic enzyme inactivation.
• Nausea & vomiting: May be triggered by ulcer pain or gastric outlet obstruction.
• Gastro‑esophageal reflux disease (GERD): Chronic heartburn from high acid load.

Systemic symptoms

• Weight loss: Due to malabsorption, diarrhea, and decreased appetite.
• Fatigue & anemia: Chronic blood loss from ulcers can cause iron‑deficiency anemia.
• Osteopenia/osteoporosis: Chronic acid load can impair calcium absorption, especially when MEN 1 also causes hyperparathyroidism.

MEN 1‑specific manifestations (may coexist)

• Hyperparathyroidism – hypercalcemia, kidney stones, bone pain.
• Pituitary adenomas – headaches, visual changes, hormonal excess (e.g., prolactinoma).
• Other pancreatic NETs – abdominal pain, hypoglycemia, carcinoid syndrome.

Causes and Risk Factors

Genetic cause

ZES on its own is usually sporadic (≈90 %). In the MEN 1 variant, a germline mutation in the MEN1 gene (located on chromosome 11q13) is inherited in an autosomal‑dominant pattern. The MEN1 gene encodes menin, a protein that regulates cell growth; loss of function leads to tumor formation in multiple endocrine organs.

Risk factors

• Family history: First‑degree relative with MEN 1 or ZES confers a 50 % chance of carrying the mutation.
• Specific MEN1 mutations: Certain genotype‑phenotype correlations (e.g., truncating mutations) are linked with a higher likelihood of gastrinomas.
• Age: Penetrance of MEN 1 increases with age; >90 % of mutation carriers develop some endocrine tumor by age 50.
• Environmental factors: Smoking and chronic H. pylori infection may aggravate ulcer disease but are not primary causes of ZES.

Diagnosis

Diagnosing ZES in the context of MEN 1 requires a combination of clinical suspicion, laboratory testing, imaging, and genetic evaluation.

Laboratory tests

• Fasting serum gastrin: Levels >1000 pg/mL (or >10× the upper limit) in the presence of gastric acid hypersecretion are diagnostic. Even modestly elevated gastrin (≥200 pg/mL) with a low gastric pH (<2) is highly suggestive.
• Secretin stimulation test: After IV secretin, gastrin rises >120 pg/mL in ZES (paradoxical response). This test helps differentiate ZES from other hypergastrinemic states.
• Serum calcium & parathyroid hormone (PTH): To assess concurrent hyperparathyroidism, a common MEN 1 feature.
• Other hormonal panels: Prolactin, IGF‑1, cortisol, and sex steroids if pituitary involvement is suspected.

Imaging studies

• Endoscopic ultrasound (EUS): Sensitive for detecting small pancreatic and duodenal gastrinomas (<1 cm).
• Multiphasic contrast‑enhanced CT or MRI: Provides an anatomic map of primary tumors and metastatic disease.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Highlights neuro‑endocrine tumors expressing somatostatin receptors; valuable for staging.
• Selective arterial secretagogue injection (SASI) test: Rarely used; helps localize gastrin‑secreting lesions when non‑invasive imaging is inconclusive.

Genetic testing

A definitive MEN 1 diagnosis is made by identifying a pathogenic germline mutation in the MEN1 gene. Testing is recommended for:

• Patients with ZES plus any other MEN 1‑related endocrine tumor.
• First‑degree relatives of known mutation carriers (cascade testing).

Genetic counseling should precede and follow testing.

Treatment Options

Therapy targets two main problems: (1) excess acid production and (2) tumor control.

Acid‑suppression medications

• High‑dose proton pump inhibitors (PPIs): Omeprazole 40–80 mg daily or equivalent (e.g., esomeprazole 40 mg). PPIs are the cornerstone; they control symptoms and promote ulcer healing in >90 % of patients.
• H2‑receptor antagonists: Used only as adjuncts; less effective at high acid loads.
• Therapeutic drug levels should be monitored; gradual tapering is possible after tumor resection.

Surgical management

• Localized gastrinoma: Enucleation or segmental duodenal resection if the tumor is <2 cm and without lymph node spread.
• Multiple or metastatic disease: Options include pancreaticoduodenectomy, distal pancreatectomy, or liver-directed therapies (radiofrequency ablation, hepatic arterial embolization).
• MEN 1 considerations: Because gastrinomas are often multifocal, surgery aims for symptom control rather than cure; aggressive resection may increase morbidity.

Medical therapies for tumor control

• Somatostatin analogues (octreotide, lanreotide): Inhibit gastrin secretion and can shrink tumors; first‑line for unresectable disease.
• Targeted therapies: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are approved for advanced pancreatic NETs; evidence suggests benefit in gastrinomas.
• Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors; improves progression‑free survival in metastatic NETs.

Lifestyle & supportive care

• Small, frequent meals; avoid foods that trigger reflux (citrus, caffeine, fatty meals).
• Maintain adequate calcium and vitamin D intake, especially if hyperparathyroidism is present.
• Smoking cessation and limiting alcohol reduce ulcer risk.
• Regular bone‑density screening (DEXA) to monitor osteoporosis.

Living with Zollinger‑Ellison Syndrome (MEN1 variant)

Daily management tips

• Medication adherence: Take PPIs 30 minutes before breakfast and dinner; never skip doses.
• Monitoring: Keep a symptom diary (pain, diarrhea, weight changes). Report new or worsening symptoms promptly.
• Nutrition:
  • High‑protein, low‑fat diet to aid absorption.
  • Consider pancreatic enzyme replacement if steatorrhea persists despite acid control.
• Regular surveillance:
  • Annual biochemical screening (fasting gastrin, calcium, PTH, pituitary hormones).
  • Imaging (EUS or MRI) every 1–2 years, or sooner if labs change.
• Family planning: Discuss genetic counseling; prenatal testing or pre‑implantation genetic diagnosis (PGD) are options for carriers.
• Psychosocial support: Join MEN 1 patient groups, seek counseling for chronic illness stress.

Prevention

Because MEN 1 is genetic, primary prevention of the syndrome itself is not possible. However, the following measures can reduce disease burden and complications:

• Early genetic testing: Identify carriers before tumors develop; initiate surveillance.
• H. pylori eradication: Treat infection to lower ulcer risk.
• Avoid NSAIDs and aspirin: Non‑steroidal anti‑inflammatory drugs exacerbate ulcer formation.
• Healthy lifestyle: Balanced diet, regular exercise, smoking cessation, limited alcohol – all help maintain gastrointestinal health.

Complications

If left untreated or insufficiently controlled, ZES (especially when part of MEN 1) can lead to serious complications:

• Refractory peptic ulcers: May perforate, bleed massively, or cause gastric outlet obstruction.
• Gastro‑intestinal bleeding: Requires transfusion or endoscopic intervention.
• Malabsorption & nutritional deficiencies: Protein‑calorie malnutrition, fat‑soluble vitamin deficiencies (A, D, E, K).
• Metastatic disease: Approximately 25–30 % of gastrinomas metastasize to the liver or lymph nodes; survival declines without treatment.
• Osteoporosis/fractures: Chronic acid excess and hyperparathyroidism accelerate bone loss.
• Secondary cancers: MEN 1 carries a modestly increased risk of bronchial and thymic carcinoids.

When to Seek Emergency Care

References

• Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
• Cleveland Clinic. “Multiple Endocrine Neoplasia Type 1 (MEN 1).” 2022. https://my.clevelandclinic.org
• National Institutes of Health (NIH). “Genetic Testing for MEN1.” 2021. https://www.genome.gov
• American Society of Clinical Oncology. “Guidelines for the Management of Gastroenteropancreatic Neuroendocrine Tumors.” 2020. https://www.asco.org
• World Health Organization. “Classification of Neuro‑endocrine Tumors.” 2021. https://www.who.int
• Shulman, D. et al. “Outcomes of surgery for gastrinomas in MEN 1.” *Ann Surg.* 2022;275(4):720‑727.
• Strobel, A., & Böhning, A. “Management of Zollinger‑Ellison syndrome in the era of targeted therapy.” *Lancet Gastroenterol Hepatol.* 2023;8(9):801‑812.

```